Mechanism of Action
Pore Formation
Protegrin-1 dimerizes and forms octameric beta-barrel pores in bacterial membranes. The pores are approximately 2 nm in diameter and allow rapid ion efflux, membrane depolarization, and cell lysis. The two disulfide bonds maintain the rigid beta-hairpin conformation required for pore assembly. Electron microscopy has confirmed toroidal pore structures in model membranes.
LPS Binding
Protegrin-1 binds lipopolysaccharide (LPS) on gram-negative bacterial outer membranes with high affinity, disrupting the outer membrane before reaching the inner membrane. This two-step mechanism explains its potent gram-negative activity. LPS binding also blocks LPS-mediated TLR4 signaling, reducing inflammatory responses in gram-negative infections.
Research Summary
Iseganan Clinical Trials
Phase 3Iseganan (IB-367), a synthetic protegrin analog, was evaluated in Phase 3 trials for prevention of oral mucositis in head and neck cancer patients receiving radiation therapy. The SWOG S0052 trial did not show a significant benefit in reducing oral mucositis severity, though activity against oral pathogens was confirmed. A Phase 3 trial for ventilator-associated pneumonia was also conducted.
Antiviral Activity
PreclinicalProtegrin-1 inhibits HSV-1, HSV-2, and HIV-1 in vitro. The mechanism involves disruption of viral envelopes and prevention of viral attachment to host cells. Retrocyclin-related studies identified similarities with theta-defensins, suggesting convergent evolution of cyclic AMP activity.
Calculate your Protegrin-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Oral rinse (clinical trial) | 3 mg/mL | 6 times daily | Oral rinse, expectorate |
| Topical bactericidal | 0.1-1 mg/mL | BID | Topical application |
Clinical development of iseganan was discontinued after Phase 3. Research use only for protegrin-1.
Interactions
Safety Profile
Protegrin-1 is hemolytic at concentrations approaching the MIC, limiting systemic use. Topical and oral wash formulations minimize systemic exposure. Iseganan was generally tolerated in oral rinse trials, with mild taste alterations and mucosal burning as the main complaints. No systemic toxicity at topical doses.
References
- [1]Kokryakov VN et al. (1993). Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Letters, 327(2), 231-236.
- [2]Trotti A et al. (2004). A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology Biology Physics, 58(3), 674-681.